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Purpose: Macular edema (ME) is a leading cause of visual loss in a range of retinal
diseases and despite the use of antivascular endothelial growth factor (anti-VEGF)
agents, its successful treatment remains a major clinical challenge. Based on the
indirect clinical evidence that interleukin-6 (IL-6) is a key additional candidate
mediator of ME, we interrogated the effect of IL-6 on blood–retinal barrier (BRB)
integrity in vitro.
Methods: Human retinal pigment epithelial cell (ARPE-19) and human retinal
microvascular endothelial cell (HRMEC) monolayers were used to mimic the outer
and inner BRB, respectively. Their paracellular permeability was assessed by measuring
the passive permeation of 40 kDa fluorescein isothiocyanate (FITC)-dextran across
confluent cells in the presence of IL-6. Transendothelial/epithelial electrical resistance
(TEER) then was measured and the distribution of the tight junction protein ZO-1 was
assessed by immunofluorescence using confocal microscopy.
Results: Treatment with IL-6 for 48 hours significantly increased the diffusion rate of
FITC-dextran, decreased TEER, and disrupted the distribution of ZO-1 in ARPE-19 cells,
which constitutively express the IL-6 transmembrane receptor, and this was reversed
with IL-6R blockade. In contrast, IL-6 did not affect the paracellular permeability, TEER,
or ZO-1 distribution in HRMECs.
Conclusions: These in vitro data support the hypothesis that IL-6 reversibly disrupts
the integrity of ARPE-19 cells, but it does not affect HRMECs.
Translational Relevance: IL-6 is a candidate therapeutic target in the treatment of
outer BRB driven ME.
Introduction
Macular edema (ME) is a leading cause of visual
impairment, and is associated with retinal barrier
dysfunction and the consequent accumulation of
extracellular fluid within the central retina.1,2 Although
a comprehensive understanding of its underlying
pathophysiology remains elusive, vascular endothelial
growth factor (VEGF) is known to have a key role in
ME associated with retinal ischemia and inflammation,
and intraocular injections of anti-VEGF agents are
now standard treatment for diabetic macula edema
(DME) and retinal vein occlusion (RVO), with
ranibizumab (Lucentis; Genentech, South San Fran-
cisco, CA) and aflibercept (Eylea; Regeneron Pharma-
ceuticals, Tarrytown, NY) being approved by the
United States Food and Drug Administration and
European Medicines Agency for these indications.
Furthermore, bevacizumab (Avastin; Roche, Basel,
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Switzerland) also is used off-label for treating retinal
diseases, including the orphan indication of uveitic ME
(UME).3–5 However, despite the visual benefits anti-
VEGF treatments have achieved, they fail to resolve
ME in .20% of patients with DME6 and in .40% of
patients with RVO and uveitis/UME,7,8 suggesting
that there also are important alternative mediators of
retinal barrier dysfunction. Principal among these is
the cytokine interleukin-6 (IL-6) as its intraocular
concentration correlates with the severity of ME in a
diverse range of retinal pathologies, including diabetic
retinopathy, DME, RVO, and uveitis.9,10–12 The
impact of IL-6 on vascular permeability already has
been studied in a variety of nonocular tissues and
cancer.13,14 Our group and others have reported
previously that in patients with refractory UME,
systemic inhibition of IL-6 signaling with the IL-6
receptor (IL-6R) monoclonal antibody tocilizumab
(TCZ – Actemra; Hoffmann-La Roche Ltd, Basel,
Switzerland) was beneficial at 6, 12, and 24
months,15–17 in particular with regard to achieving
a reduction in central retinal thickness where other
therapies had failed. However, the direct effect of IL-
6 on the human blood retinal barrier (BRB) is yet to
be fully elucidated. Therefore, we designed the
present laboratory study to model the inner BRB
using human retinal microvascular endothelial cells
(HRMEC) and the outer BRB using human retinal
pigment epithelial (ARPE-19) cells, with the goal of
interrogating the effects of IL-6 and IL-6R blockade
on in vitro measures of BRB integrity.
Materials and Methods
Cell Culture
To mimic the outer BRB, a spontaneously arising
ARPE-19 cell line was obtained from the American
Type Culture Collection (ATCC). ARPE-19 cells then
were cultured in a 50:50 mixture of Dulbecco
modified Eagle medium (DMEM) and Ham’s F12
(PAA) supplemented with 10% fetal bovine serum
(FBS, PAA), 2 mM L-glutamine (PAA), 100 U/mL
penicillin (PAA), 0.1 mg/mL streptomycin (PAA),
and 1 mM sodium pyruvate (Sigma-Aldrich Corp., St.
Louis, MO) in a humidified incubator at 378C in 5%
CO2. Cells were passaged every 4 to 5 days by
trypsinization.
For the inner BRB, HRMEC cells (ACBRI 181)
purchased from Cell Systems Corporation (Kirkland,
WA) were cultured in MV2 growth medium (Promo-
Cell) containing 5.5 mM glucose, 0.5 ng/mL VEGF,
5% FBS, 5 ng/mL EGF, 10 ng/mL bFGF, 20 ng/mL
IGF, 1 lg/mL ascorbic acid, 100 U/mL penicillin, and
0.2 lg/mL hydrocortisone. Because VEGF is a major
initiator of barrier breakdown we tested the effect of
VEGF-A on transendothelial electrical resistance
(TEER) in HRMEC with concentrations ranging
from 0.3 to 80 ng/mL (Supplementary Fig. S1),
observing that at concentrations below 5 ng/mL,
VEGF-A does not induce significant loss of endo-
thelial cell barrier. This confirmed that the concen-
trations of VEGF-A in the MV2 medium used for
our experiments is 10-fold below the threshold
needed to affect HRMEC integrity in our in vitro
system, and, hence, this will not influence our results.
Cells were fed triweekly and passaged every 4 to 5
days by trypsinization. For all experiments, cells
were used after 4 to 9 passages. For experiments
measuring IL-6R expression in HRMEC, cells were
cultured in either full growth medium as above or in
starvation medium, composed of MV2 medium
(PromoCell) containing 5.5 mM glucose and 0.5%
FBS only.
For immunofluorescence, cell suspensions of 1 3
105 cells/mL were seeded onto glass coverslips and
incubated overnight. Cells then were stimulated with
or without IL-6 (R & D Systems, Minneapolis, MN)
for 24 to 48 hours. To test the ability of IL-6R
blockade to reverse the effects IL-6, cells were treated
with 200 ng/mL TCZ either simultaneously or 24
hours after IL-6 stimulation.
Permeability Assay
The paracellular permeability of ARPE-19 and
HRMEC monolayers was assessed by measuring
the passive permeation of fluorescein isothiocya-
nate (FITC)-dextran (40 kDa, Sigma-Aldrich
Corp.) across confluent cells grown on Transwell
filters (Costar, 12 mm diameter, 0.4 lm pore size).
For monolayer culture, cells were seeded at 23 105
cells/cm2.
For ARPE-19 cells, monolayers were cultured for 2
to 3 weeks in medium containing 1% FBS, changing
the medium every 3 days. At day 19, cells were treated
with IL-6 (200 and 400 ng/mL) for 48 hours. At day
21, 500 lg/mL fluorescein isothiocyanate FITC-
dextran were added to the apical compartment of the
chamber and samples (200 lL) from the basal medium
(lower chamber) were collected 120 minutes after
addition of FITC-dextran. The absorbance of basal
and apical medium samples was measured at 485 nm of
excitation and 528 nm of emission in a microplate
reader (SpectraMax Gemini; Molecular Devices, San
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Jose, CA). Each condition was assayed in triplicate and
repeated in at least three independent experiments. The
diffusion rate was expressed as a percentage and
calculated as follows: (amount of dextran lower
chamber)3 100/(amount of dextran upper chamber).
For HRMEC permeability assays, cells were
cultured on Transwell filters for 14 days. At day 12,
cells were treated with IL-6 (200 and 400 ng/mL) for 48
hours and at day 14, FITC-dextran was added to the
apical compartment of the chamber and the para-
cellular permeability was measured as described above.
Measurement of TEER
For ARPE-19 cells (grown in monolayers on
Transwell filters as described above), TEER was
measured using a commercial electrical resistance
system (Millicell; Millipore). TEER values were
calculated by subtracting the value of a blank
(Transwell filter without cells) and expressed as
resistance/area (X/cm2) relative to the resistance/area
of the baseline at day 3. Measurements were repeated
at least three times for each filter, and each
experiment was repeated at least four times using
two filters.
In HRMEC, TEER was measured using the
CellZscope system (NanoAnalytics, Munster, Ger-
many) in cell monolayers grown on transwells as
described above. TEER was measured continuously in
a CO2 incubator at 378C. TEER values were expressed
as resistance/area (X/cm2) relative to the resistance
before the addition of IL-6. Measurements were
collected from three filters per experimental condition.
Immunofluorescence
The distribution of the tight junction protein 1,
also known as ZO-1, in ARPE-19 monolayers was
examined by immunofluorescence. Cells grown on
cover slides were fixed with 4% paraformaldehyde in
PBS for 15 minutes at room temperature (RT) and
washed three times with PBS. Cells then were
permeabilized with 0.2% Triton X-100 in PBS for 15
minutes and blocked twice with filtered 1% bovine
serum albumin. Cells were incubated with primary
antibody anti-ZO-1 (Invitrogen, Carlsbad, CA) over-
night, before washing with PBS, and final incubations
with secondary antibody Alexa Fluor anti-mouse 488
IgG for 1 hour at RT. Nuclei were counterstained
with 40,6-diamidino-2-phenylendole (DAPI). Controls
were stained with secondary antibodies only. Stained
cells were washed and covered with Prolong Gold
antifade reagent (Life Technologies, Carlsbad, CA).
Images of immunostained cells were captured using a
Leica TCS SP5 (Leica, Wetzlar, Germany) confocal
laser scanning microscope, imaged with an APO363
objective. The area and intensity covered by mem-
brane ZO-1 were calculated using Image J.
Quantification of IL-6R in HRMEC
To quantify HRMEC IL-6R expression, cells were
plated at 30,000 cells per well in 96-well culture plates
and grown in either growth or starvation medium for
72 hours. At the end of the growth period,
conditioned medium was harvested and cell cultures
washed twice with PBS-Ca2þ, Mg2þ (Life technolo-
gies), and once with 50 lL dissociation reagent (Life
Technologies). After washing, cells were detached
from the plates by incubation with 100 lL cell
dissociation reagent and transferred to a flow
cytometry plate (Corning, Corning, NY). The original
wells were washed once with 100 lL PBS-Ca2þ,
Mg2þ (Life Technologies) and the wash solution
containing remaining cells added to the flow cytom-
etry plate. Cells were pelleted by centrifugation at
300g for 5 minutes and the supernatant discarded.
Pellets were resuspended in MACS buffer (PBS
containing 2% FBS and 2 mM ethylenediaminetetra-
acetic acid [EDTA]) containing 10 lg/mL human IgG
(Sigma-Aldrich Corp.) to block nonspecific binding
sites and incubated for 15 minutes at RT. Following
blocking of nonspecific binding, anti-human IL-6Ra-
PE, anti-human VEGF-R1-PE or isotype control
antibody (R & D Systems) were added to the cells and
the reaction incubated for 45 minutes at 28C to 88C.
Following staining, cells were pelleted by centrifuga-
tion at 300g for 5 minutes and the pellet resuspended
in 110 lL MACS buffer. PE fluorescence was
measured using a BD LSRII flow cytometer.
Soluble IL-6R was quantified in conditioned
growth and starvation medium using a Luminex
high-performance IL-6R assay (R & D Systems),
according to the manufacturer’s instructions. Non-
conditioned medium also was quantified as a control.
Samples were diluted 1:1 and measured in duplicate
using a Luminex 200 system.
Statistical Analysis
Results are expressed as mean 6 standard devia-
tion (SD). Student’s t-test or analysis of variance
(ANOVA) as appropriate were used to determine
statistical significance between treatments. P , 0.05
was considered significant. All calculations were
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performed using GraphPad Prism (GraphPad Soft-
ware, San Diego, CA).
Results
IL-6 Increases Paracellular Permeability With
Concomitant Decrease in TEER in ARPE-19
Monolayers
To determine the effect of IL-6 on outer BRB
integrity, we first assessed the effect of IL-6 on the
paracellular permeability of ARPE-19 cell monolay-
ers, which constitutively express the IL-6 transmem-
brane receptor,18,19 by measuring the transcellular
diffusion rate of FITC-dextran (40 kDa). As shown in
Figure 1A, treatment with IL-6 (200 and 400 ng/mL)
for 48 hours significantly increased the diffusion rate
of FITC-dextran in a dose-dependent manner (P ,
0.05 vs. control). We next determined the effect of IL-
6 on ARPE-19 monolayer TEER. In line with our
findings on paracellular permeability, TEER was
significantly reduced as shown in Figure 1B, and this
was evident after 24 hours of stimulation (day 13).
IL-6 Alters the Expression of ZO-1 in ARPE-19
Cells
As we had demonstrated increased permeability
and decreased TEER in ARPE-19 monolayers we
proceeded to test the effect of IL-6 on tight junctions
by assessing the distribution of ZO-1. In untreated
cells, ZO-1 expression was continuous and regular.
The expression demarcated the cell membranes and
was particularly intense at contact points in the
monolayer. However, following exposure to 400 ng/
mL of IL-6 (the concentration that induced the
greatest effect in permeability and TEER disruption)
for 48 hours, the monolayer distribution of ZO-1 was
disturbed. The abnormal distribution of ZO-1 man-
ifested as diffuse cytoplasmic distribution and frag-
mented membrane staining (Figs. 1C, 1D).
IL-6R Blockade Inhibits IL-6-Induced Outer
BRB Disruption
To assess whether IL-6R inhibition reversed IL-6–
induced barrier disruption, ARPE-19 cells grown on
filters to confluence were treated with TCZ (400 ng/
mL) for 24 hours following IL-6 stimulation. The
paracellular permeability and TEER was determined
after a further 24 hours. As shown in Figure 2, TCZ
significantly reversed IL-6–induced barrier disrup-
tion. These data demonstrated a significant TCZ
associated reduction in (A) paracellular permeability
and (B) TEER in ARPE-19 monolayers (P , 0.05).
Finally, to test the ability of IL-6R inhibition to
prevent IL-6–induced barrier disruption, ZO-1 distri-
bution also was determined in ARPE-19 cells (Fig. 3)
treated with TCZ. In these experiments, TCZ was
either added simultaneously with IL-6 for 48 or 24
hours after IL-6 stimulation. TCZ was able to restore
ZO-1 distribution in IL-6–treated cells when added
simultaneously with IL-6. Conversely, when cells were
treated with TCZ alone in a deferred manner, ZO-1
distribution was similar to that of untreated cells.
IL-6 Fails to Induce Disruption of the Inner
BRB
IL-6 can activate cellular signaling via two
mechanisms: the classic or cis form of signaling,
triggered by the binding of the ligand to transmem-
brane IL-6R, and the trans-signaling pathway in-
duced by activity of the soluble IL-6R on
ubiquitously-expressed gp130.18 To determine wheth-
er IL-6–induced endothelial barrier breakdown could
be triggered by IL-6–signaling as observed in ARPE-
19 cells, we investigated IL-6R expression in
HRMEC. Using flow cytometry, we did not observe
expression of transmembrane IL-6R in HRMEC
cultured in either full growth or starvation medium,
when compared to the labeling produced by the
isotype control antibody (Fig. 4A). As expected,
surface expression of the endothelial cell marker
VEGF-R1 was readily detectable (Fig. 4A).
Consequently, we measured sIL-6R within the
conditioned medium of HRMEC cultured under
growth or starvation conditions. We found that sIL-
6R was detectable at a low level in HRMEC
conditioned medium and significantly enriched under
full growth conditions. Contrarily, IL-6R was unde-
tectable in nonconditioned HRMEC medium (Fig.
4B). However, this enrichment of sIL-6R in full
growth conditions remained insufficient to mediate
IL-6–induced barrier breakdown as the transcellular
diffusion rate of FITC-dextran, TEER and ZO-1
distribution was unaltered by the addition of IL-6
alone to our HRMEC cultures (Fig. 5). The
endogenous secretion of IL-6 by HRMEC was very
low (Supplementary Fig. S2).
Discussion
The functional integrity of the inner and outer
BRB is critical for the maintenance of neural retinal
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health and is dependent on the expression of
transmembrane proteins, which are anchored to the
actin cytoskeleton.20 This permits restricted para-
cellular permeability and high TEER.21,22 Our results
suggested that the effects of IL-6 compromise this
barrier function in retinal microvascular endothelial
and retinal pigment epithelial cells. Furthermore,
changes in the distribution of ZO-1 are likely to have
altered the diffusion rate of FITC-dextran in ARPE-
19 cells as IL-6 clearly decreased ZO-1 membrane
staining. However, tight junctions are highly complex
structures, and the relative contribution of the various
proteins to the barrier function remains unclear.
Thus, in addition to the disorganization of ZO-1, IL-6
also might modulate other pathways associated with
cellular permeability.1
Our findings are consistent with prior reports
implicating IL-6 in the pathogenesis of ME in human
and preclinical in vitro and in vivo experimental
systems,22–26 by decreasing expression of VE-cadher-
in, occludin, and claudin-5,27 and increasing VEGF-
mediated vascular permeability via STAT3 activa-
tion.28,29 However, our human-derived cell cultures
imply that in man, the principal effect of IL-6 is on
retinal pigment epithelial cells, that is, the outer BRB.
In our HRMEC assay system, we did not detect
expression of cell-surface transmembrane IL-6R, but
low levels of soluble IL-6R were quantifiable in the
Figure 1. Effect of IL-6 on paracellular permeability, TEER, and ZO-1 distribution in ARPE-19 cells. ARPE-19 cells grown on Transwells
were treated with different concentrations of IL-6 for 48 hours and the diffusion rate of FITC-dextran (N ¼ 7) (A) and TEER (B) were
determined (N¼ 4). Values are expressed as mean 6 SD and statistical analysis was performed by Student’s t-test. *P , 0.05. ARPE-19
cells also were treated with IL-6 (400 ng/mL) for 48 hours, fixed, and immunostained with anti ZO-1 (green) and DAPI (blue) (C). Images
shown are representative of three independent experiments. Scale bar: 25 lm.
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Figure 2. Effect of TCZ on IL-6–induced barrier disruption. ARPE-19 cells grown on filters were treated with IL-6 for 24 hours and then
with TCZ for 24 hours. Cell permeability as determined by FITC-diffusion rate (A) and TEER (B) were measured (N ¼ 5). Values are
expressed as mean 6 SD and statistical analysis was performed by Student’s t-test. *P , 0.05 vs. control, #P , 0.05 versus IL-6 þ TCZ.
Figure 3. Effect of IL-6 blockade on the distribution of ZO-1 in ARPE-19 cells. Cells were treated with IL-6 (400 ng/mL) for 48 hours, and
TCZ was either added simultaneously with IL-6 or 24 hours afterwards. Cells then were fixed and immunostained with anti ZO-1 (green)
and DAPI (blue). Images shown are representative of three independent experiments (A). Scale bar: 25 lm. Membrane ZO-1 staining was
quantified with Image J measuring the Integrated density (area times mean fluorescence intensity (B). Values are expressed as mean 6
SD and statistical analysis was performed by Student’s t-test. *P , 0.05 versus control, #P , 0.05 versus IL-6 þ TCZ (N ¼ 5).
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conditioned medium of these cells and enriched under
conditions of cell growth. We suggested that this
soluble IL-6R is either produced by the cleavage of a
limited quantity of transmembrane IL-6R not easily
detectable by flow cytometry or directly by the
production and release of alternatively-spliced soluble
IL-6R.30,31 Nonetheless, this was in insufficient
concentrations to mediate loss of HRMEC integrity
in our in vitro system. However, in vivo, soluble IL-
6R has been detected in the aqueous humor of eyes
with uveitis,32 and it is plausible that if this is present
in higher concentrations than detected in our cultures,
inner BRB disruption still may ensue. Hence, further
investigation of the source of soluble IL-6R in these
cellular systems, as well as in vivo, is warranted to
fully interrogate whether IL-6 trans-signaling may
still contribute to breakdown of the inner BRB and
consequent ME.
In keeping with this, the main limitation of our
study was the use of monoculture systems to mimic
the inner and outer BRB. Although HRMECs are
isolated from normal human retinal tissue, the human
ARPE-19 cell line has been criticized for the
divergence in some of its characteristics from normal
healthy human RPE.33 However, these limitations
were partially addressed by the use of Transwell
inserts instead of traditional cell culture plates as
these allow ARPE-19 polarization. Future studies
would nonetheless benefit from the use of pluripotent
stem cell-derived RPE and organ-on-a-chip ap-
proaches involving multiple cell types to better
characterize the BRB. Another caveat of our work
is the use of high concentrations of IL-6. The range of
IL-6 concentrations previously reported in the context
of in vitro systems is highly variable with some
investigators matching the concentrations applied in
our experiments,34–36 while others use concentrations
in the range of 20 to 100 ng/mL.28,29 This lack of
standardization threatens comparability between
studies, and it is possible that the concentrations used
in our in vitro systems will have limited relevance in
vivo.
In summary, our data supported a key role for IL-
6 in disrupting the outer BRB as its addition to in
vitro cultures of ARPE-19 cells increased para-
cellular permeability, decreased TEER, and altered
ZO-1 distribution, and these effects were abrogated
by blockade of the IL-6R with TCZ. However, IL-6–
induced disruption of HRMEC integrity was not
seen at the concentrations of soluble IL-6R present
in our in vitro culture system. Nonetheless, our
observed effect of IL-6 on the integrity of the outer
BRB support the continued evaluation of the
inhibition of combinations of soluble mediators of
vascular permeability, including IL-6 using enhanced
in vitro and in vivo experimental systems with a view
to clinical translation for sight-threatening ME
associated with diabetic retinopathy, RVO, and
uveitis.
Figure 4. IL-6R expression in HRMEC. (A) IL-6R and VEGF-R1 surface expression in HRMEC grown in full growth or starvation medium
were quantified using flow cytometry. Mean fluorescence intensity (MFI) of the labeling produced by the specific antibody is shown in
comparison with the labeling produced by the isotype control antibody. Values represent mean 6 SD, n¼ 4 per condition. (B) Soluble IL-
6R detection in conditioned medium from HRMEC grown under full growth or starvation conditions. Values are expressed as mean 6 SD,
n ¼ 4 per condition. Soluble IL-6R was undetectable in nonconditioned medium.
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